The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Solazyme's revenues will wither -37.2% and EPS will remain in the red.
The average estimate for revenue is $8.5 million. On the bottom line, the average EPS estimate is -$0.39.
Last quarter, Solazyme reported revenue of $8.4 million. GAAP reported sales were 43% lower than the prior-year quarter's $14.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at -$0.35. GAAP EPS were -$0.40 for Q4 against -$0.26 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 83.3%, much worse than the prior-year quarter. Operating margin was -296.5%, much worse than the prior-year quarter. Net margin was -292.1%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $55.3 million. The average EPS estimate is -$1.32.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 381 members out of 399 rating the stock outperform, and 18 members rating it underperform. Among 81 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 72 give Solazyme a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Solazyme is outperform, with an average price target of $17.08.
Is Solazyme the right energy stock for you? Read about a handful of timely, profit-producing plays on expensive crude in "3 Stocks for $100 Oil." Click here for instant access to this free report.
- Add Solazyme to My Watchlist.